ClinicalTrials.gg
Active, not recruitingNCT04544462Updated Aug 26, 2025

ANXA5 M2 Haplotyping in IVF Patients and Embryos

An observational study in Infertility, Miscarriage, Recurrent and Pregnancy Complications, sponsored by Genomic Prediction Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Genomic Prediction Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Planned enrollment
30th of 119
500 · median 150
Started
2020
with 19 others
Observational
119 of 395
25 open now
Primary completion
2026-11
later than 23 of 82 live
Registered
305th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 30th largest by planned enrollment of the 119 observational ones that give a count, is one of 20 that started in 2020, is one of 119 observational ones, reaches primary completion later than 23 of the 82 other live ones, and was the 305th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

This study aims to characterize the association between history of pregnancy complications and M2 carrier status in IVF patients and the utility of M2 haplotype preimplantation genetic testing (PGT) in embryos produced by carrier couples. Participants in this study will be screened for the M2 variant. History of pregnancy complications and miscarriages will be studied in order to determine potential associations with M2 carrier-ship.

Read the detailed description

Patients consenting to participation in the study will receive a saliva collection kit for M2 testing. Genomic Prediction Clinical Laboratory will perform testing and issue a report per routine clinical procedures. Upon completion of issuing a report, the patients' medical records will be obtained from the IVF Center providing care to the patient. Information obtained may include: history of miscarriage, embryo transfer outcomes, preeclampsia, small for gestation age baby, or thrombophilia disorders.

In addition to obtaining records related to history of pregnancy complications, carrier couples will be offered the use of preimplantation genetic testing for M2 carrier status (PGT-M2) in their embryos. Patients electing to perform PGT-M2 will receive PGT-A according to standard clinical practice, along with M2 carrier status.

A total of 500 patients will complete the study and may be recruited from any IVF clinic in the United States. Patients will undergo ovarian hyper-stimulation, oocyte retrieval, fertilization and embryo culture per standard clinical protocol determined by each clinic.

03

Conditions studied

  • Infertility
  • Miscarriage, Recurrent
  • Pregnancy Complications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All couples above the age of 18 seeking infertility treatment at IVF centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All couples above the age of 18

Exclusion criteria

Exclusion Criteria:

  • Any case where biological parental DNA is unavailable.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Infertile patients

    Patients attending an IVF center for infertility treatment

    Other: M2 Test

Interventions

  • OtherM2 Test

    DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.

06

What researchers measure

Primary outcomes

  1. M2 Haplotype frequency

    Frequency of carriers of the M2 haplotype attending an IVF center for infertility treatment.

    Time frame: 1 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Nov 2026, 81 months after the start.

Of 240 observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2020
First posted
Sep 10, 2020
StartActual
Feb 10, 2020
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04544462
Lead sponsor
Genomic Prediction Inc.
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Feb 10, 2020
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion